T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAFV600E Mutation in Papillary Thyroid Carcinoma

T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAFV600E Mutation in Papillary Thyroid Carcinoma

Papillary thyroid cancer (PTC) is the most common malignant disease in endocrine systems. T-box transcription factor 22 (TBX22) is a phylogenetically conserved family member that has not been widely characterized in cancers. In this study, we explored the potential clinical significance and biologic...

Full description

Bibliographic Details
Main Authors:	Xubin Dong, Jingjing Song, Jing Hu, Cheng Zheng, Xiaohua Zhang, Haiguang Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-12-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	TBX22 papillary thyroid cancer biomarker tumor microenvironment BRAFV600E RAS
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2020.590898/full

Similar Items

Major Vault Protein (MVP) Associated With BRAFV600E Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer via MAPK/ERK and PI3K/AKT Pathways
by: Xubin Dong, et al.
Published: (2022-03-01)

Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules
by: Tatiana Marina Vieira Giorgenon, et al.
Published: (2019-03-01)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
by: Yan-Yu Lin, et al.
Published: (2023-01-01)

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital
by: Harahap AS, et al.
Published: (2023-05-01)

Comparative study on different clinical features and BRAFV600E mutation rate of papillary thyroid carcinoma
by: Sun Jing, et al.
Published: (2021-12-01)

BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters
by: Faruk Erdem KOMBAK, et al.
Published: (2019-05-01)

Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma
by: Xiaoquan Hong, et al.
Published: (2024-01-01)

Association between BRAFV600E mutation and the clinicopathological features in incidental papillary thyroid microcarcinoma: A single-center study in Turkish patients
by: Havva Sezer, et al.
Published: (2020-08-01)

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation
by: Yilamujiang Ainiwan, et al.
Published: (2025-03-01)

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
by: Dong Chen, et al.
Published: (2023-01-01)

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
by: Shuhui Huang, et al.
Published: (2022-11-01)

Diagnostic value of FNAC combined with BRAFV600E mutation detection in Hashimoto’s thyroiditis complicated with papillary thyroid carcinoma
by: Jingyao Fu, et al.
Published: (2024-05-01)

X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
by: Sandeep Kumar Parvathareddy, et al.
Published: (2022-12-01)

Clinicopathological Implications of the BRAFV600E Mutation in Papillary Thyroid Carcinoma of Ukrainian Patients Exposed to the Chernobyl Radiation in Childhood: A Study for 30 Years After the Accident
by: Liudmyla Zurnadzhy, et al.
Published: (2022-04-01)

Modified TI-RADS Coupled with BRAFV600E Enhances Diagnostic Efficiency in Papillary Thyroid Carcinoma: Prospective Study
by: Wang J, et al.
Published: (2024-07-01)

Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
by: Raffaella De Paolo, et al.
Published: (2023-07-01)

Clinical outcome, role of BRAFV600E, and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?
by: Carmelo eNucera, et al.
Published: (2012-02-01)

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy
by: Guoquan Zhu, et al.
Published: (2019-05-01)

Integrating BRAFV600E mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma
by: Zheng Zhang, et al.
Published: (2022-04-01)

BRAFV600E mutation and DSS treatment synergize to induce cecal tumor formation in mice
by: Chenxi Gao, et al.
Published: (2024-03-01)

BRAFV600E Mutation-Responsive miRNA-222-3p Promotes Metastasis of Papillary Thyroid Cancer Cells via Snail-Induced EMT
by: Yuan Gao, et al.
Published: (2022-05-01)

Elucidating the Prognostic Role of BRAFV600E and the Activation Status of the Downstream MAPK Pathway in PTC: A Study from a Tertiary Centre in India
by: Nadeem Kocheri, et al.
Published: (2024-12-01)

Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
by: Qianqian Xu, et al.
Published: (2024-06-01)

The association between BMI and BRAFV600E mutation may differ by primary tumor size
by: Hyunju Park, et al.
Published: (2024-10-01)

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules
by: Huang G, et al.
Published: (2023-12-01)

Profile and clinical implication of circular RNAs in human papillary thyroid carcinoma
by: Huihui Ren, et al.
Published: (2018-08-01)

AI‐BRAFV600E: A deep convolutional neural network for BRAFV600E mutation status prediction of thyroid nodules using ultrasound images
by: Chuang Xi, et al.
Published: (2023-04-01)

Targeting miR‐31 represses tumourigenesis and dedifferentiation of BRAFV600E‐associated thyroid carcinoma
by: Peitao Zhang, et al.
Published: (2024-05-01)

Immunohistochemical Detection of BRAFV600E in Cutaneous Melanocytic Neoplasms in a Cohort of Egyptian Population
by: Nada M. Yakout, et al.
Published: (2022-12-01)

BRAFV600E mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
by: Nada M. Yakout, et al.
Published: (2023-02-01)

Rethinking the role of oncogenes in papillary thyroid cancer initiation
by: Mario eVitale
Published: (2012-06-01)

FAK loss reduces BRAFV600E-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formation
by: Chenxi Gao, et al.
Published: (2024-06-01)

The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old
by: Yasemin Giles Şenyürek, et al.
Published: (2022-06-01)

Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer
by: Jingran Ji, et al.
Published: (2023-01-01)

Relationship of the recurrence after pterygium surgery with the presence of HSV, EBV, CMV, HPV, and BRAFV600E mutation
by: S.O. Rykov, et al.
Published: (2019-02-01)

Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1H-pyrazole as highly selective and potent BRAFV600E and CRAF inhibitor
by: Jinwoong Kim, et al.
Published: (2019-01-01)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
by: Iris Car, et al.
Published: (2023-04-01)

Indolent renal involvement with BRAFV600E mutation: Erdheim‐Chester, a rare disease with a wide spectrum of clinical manifestations
by: Charlotte Vanhomwegen, et al.
Published: (2021-08-01)

How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
by: Noha Mukhtar, et al.
Published: (2023-10-01)

The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E‐transformed cells
by: Tobias Furlan, et al.
Published: (2018-06-01)